|Bid||53.11 x 800|
|Ask||53.18 x 1000|
|Day's Range||53.03 - 53.25|
|52 Week Range||47.88 - 67.76|
|Beta (5Y Monthly)||0.23|
|PE Ratio (TTM)||23.30|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jul 08, 2021|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for RDY
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.
Eton Pharmaceuticals Inc (NASDAQ: ETON) has sold its hospital products to Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories Ltd (NYSE: RDY), for $50 million. "The sale of our hospital products allows us to focus our resources on our core rare disease business, which is rapidly growing, and also provides an attractive opportunity to monetize the value we have created with our hospital products," said CEO Sean Brynjelsen, CEO of Eton. Dr. Reddy's purchased the Biorphen, Rezipre